Systemic lupus erythematosus natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 5: Line 5:
Common complications of systemic lupus erythematosus include dermatitis, nephritis and arthiritis. Prognosis is generally poor, and the 10-year mortality rate of patients with systemic lupus erythematosus is approximately 40%. The disease course can be divided into 4 subcategories based on the course of the disease: developmental phase, preclinical phase, clinical phase, and comorbid complication phase.
Common complications of systemic lupus erythematosus include dermatitis, nephritis and arthiritis. Prognosis is generally poor, and the 10-year mortality rate of patients with systemic lupus erythematosus is approximately 40%. The disease course can be divided into 4 subcategories based on the course of the disease: developmental phase, preclinical phase, clinical phase, and comorbid complication phase.
==Natural History==
==Natural History==
*Systemic lupus erythematosus (SLE) is an [[autoimmune disease]]. SLE is a disease of waxing and waning, with a lot of flare up episodes. SLE usually develop in the second and third decade of life, although it can develop in any age, and start with mild symptoms such as [[fatigue]], fever, and skin [[rashes]]. Without treatment, the patient will develop symptoms of end organ damage, which will eventually lead to death in most of the patients.
*Systemic lupus erythematosus (SLE) is an [[autoimmune disease]]. SLE is a disease of waxing and waning, with possible flare up episodes. SLE usually develops in the second and third decade of life, although it can presents any age, and start with mild symptoms such as [[fatigue]], fever, and skin [[rashes]]. Without treatment, the patient will develop symptoms of end organ damage, which will eventually lead to death in most of the patients.
*The disease course can be divided into 4 subcategories based on the course of the disease:
*The disease course can be divided into 4 subcategories based on the course of the disease:
   
   
Line 32: Line 32:
*[[Malignancies]]
*[[Malignancies]]


=== Flare up associated factors: ===
=== Factors associated with flare up: ===
* Stress (emotional etc.)
* [[Stress]] (emotional etc.)
* Sunlight
* [[Sunlight]]
* Ultraviolet light
* [[Ultraviolet]] light
* Infection
* [[Infection]]
* Injuries
* Injuries
* Surgery
* [[Surgery]]
* Pregnancy
* [[Pregnancy]]
* Abrupt discontinuation of medications
* Abrupt discontinuation of medications
* Treatment noncompliance
* Treatment noncompliance
Line 53: Line 53:
!Frequency
!Frequency
|-
|-
| rowspan="8" |Gastrointestinal involvement
| rowspan="8" |Gastrointestinal system
|[[Dysphagia]]
|[[Dysphagia]]
|
|
* The most frequent gastrointestinal complaint and is usually due to an underlying esophageal motility disorder, concomitant gastroesophageal reflux disease
* The most frequent gastrointestinal complaint and is usually due to an underlying esophageal motility disorder, concomitant [[gastroesophageal reflux disease]].
|
|
|-
|-
|[[Peptic ulcer disease]]
|[[Peptic ulcer disease]]
|
|
* May be due to the disease itself or the effect of SLE treatment
* May be due to the disease itself or the effect of SLE treatment.
|
|
|-
|-
|[[Intestinal pseudo-obstruction|Intestinal pseudo-obstruction]]
|[[Intestinal pseudo-obstruction|Intestinal pseudo-obstruction]]
|
|
* A rare complication of SLE and lead to mechanical obstruction of the small or large bowel in the absence of an anatomic lesion obstructing the flow of intestinal contents
* A rare complication of SLE and lead to mechanical obstruction of the small or large bowel in the absence of an anatomic lesion obstructing the flow of intestinal contents.
|
|
|-
|-
|[[Protein-losing enteropathy|Protein-losing enteropathy]]
|[[Protein-losing enteropathy|Protein-losing enteropathy]]
|
|
* It typically occurs in patients with clinically severe SLE with multi-organ involvement and characterized with the onset of profound edema and hypoalbuminemia in the absence of nephrotic range proteinuria
* It typically occurs in patients with clinically severe SLE with multi-organ involvement and characterized with the onset of profound edema and [[hypoalbuminemia]] in the absence of nephrotic range [[proteinuria]].
|
|
|-
|-
|[[Hepatitis]]
|[[Hepatitis]]
|
|
* May be due to a wide range of factors including drug-induced damage, steatosis, viral hepatitis, vascular thrombosis, overlap with autoimmune hepatitis, or SLE itself
* May be due to a wide range of factors including drug-induced damage, steatosis, viral hepatitis, vascular thrombosis, overlap with autoimmune hepatitis, or SLE itself.
|
|
|-
|-
|[[Acute pancreatitis|Acute pancreatitis]]
|[[Acute pancreatitis|Acute pancreatitis]]
|
|
* It occurs usually in the setting of active SLE
* It occurs usually in the setting of active SLE.
|
|
|-
|-
|[[Mesenteric vascular occlusion|Mesenteric vasculitis]]
|[[Mesenteric vascular occlusion|Mesenteric vasculitis]]
|
|
* Most often this involves medium-sized branches of the celiac, superior mesenteric, and inferior mesenteric arteries. Features of mesenteric vasculitis include abdominal pain or gastrointestinal bleeding with intestinal ischemia, infarction, perforation, or pancreatitis  
* Most often this involves medium-sized branches of the [[Celiac artery|celiac]], [[Superior mesenteric artery|superior mesenteric]], and [[Inferior mesenteric artery|inferior mesenteric arteries]]. Features of [[mesenteric]] [[vasculitis]] include [[abdominal pain]] or [[gastrointestinal bleeding]] with [[intestinal ischemia]], infarction, perforation, or [[pancreatitis]].
* Primary peritonitis: an infection that develops in the peritoneum mainly due to lupus vasculitis
* [[SBP|Primary spontaneous peritonitis]]: an infection that develops in the [[peritoneum]] mainly due to lupus [[vasculitis]].
|
|
|-
|-
|[[Acute cholecystitis]]
|[[Acute cholecystitis]]
|
|
* Due to periarterial fibrosis and acute vasculitis
* Due to periarterial [[fibrosis]] and acute vasculitis
* It can progress to gangrene, perforation, and sepsis.
* It can progress to [[gangrene]], perforation, and [[sepsis]].
|
|
|-
|-
Line 99: Line 99:
|[[Pleural disease|Pleural disease]]
|[[Pleural disease|Pleural disease]]
|
|
* [[Pleuritis]] can lead to pleuritic chest pain with or without radiographic evidence of a pleural effusion. Pleuritis is a disease state in which there is inflammation of the [[pleura]], the lining of the [[pleural cavity]], surrounding the [[Lung|lungs]].
* [[Pleuritis]] can lead to [[pleuritic chest pain]] with or without radiographic evidence of a [[pleural effusion]]. Pleuritis is a disease state in which there is [[inflammation]] of the [[pleura]], the lining of the [[pleural cavity]], surrounding the [[Lung|lungs]].
* [[Pneumothorax]]: a collection of air within the pleural cavity
* [[Pneumothorax]]: a collection of air within the pleural cavity.
|
|
|-
|-
|[[Pneumonitis|Acute pneumonitis]]
|[[Pneumonitis|Acute pneumonitis]]
|
|
* A rare and fulminant form of diffuse lung injury that generally occurs in previously healthy individuals and has a rapid onset with fever, cough, and shortness of breath
* A rare and fulminant form of diffuse lung injury that generally occurs in previously healthy individuals and has a rapid onset with [[fever]], [[cough]], and [[Dyspnea|shortness of breath]].
|
|
|-
|-
Line 112: Line 112:
* Pulmonary alveolar hemorrhage:
* Pulmonary alveolar hemorrhage:
** A rare complication
** A rare complication
** Acutely ill patients with hemoptysis, fever, cough, and hypoxemia, and blood loss can be extensive
** Acutely ill patients with [[hemoptysis]], [[fever]], [[cough]], and [[hypoxemia]].
** Blood loss can be extensive.
** Associated with high mortality rates of 70%–90%
** Associated with high mortality rates of 70%–90%
|
|
Line 118: Line 119:
|[[Pulmonary hypertension]]
|[[Pulmonary hypertension]]
|
|
* An increase in blood pressure in the [[pulmonary artery]] or [[lung]] [[Pulmonary circulation|vasculature]], leading to [[Dypsnea|shortness of breath]], [[dizziness]], [[fainting]], and other symptoms, all of which are exacerbated by exertion
* Increased pressure in the [[pulmonary artery]] or [[lung]] [[Pulmonary circulation|vasculature]] presents with exertional [[Dypsnea|shortness of breath]], [[dizziness]], and [[faint]].
|
|
|-
|-
|[[Thromboembolic disease]]
|[[Thromboembolic disease]]
|
|
* Chronic inflammation during the disease flare ups is an important characteristic in SLE patients that increase the risk of thromboembolic events
* Chronic [[inflammation]] during the disease flare ups is an important characteristic in SLE patients that increase the risk of thromboembolic events.
|
|
|-
|-
|Shrinking lung syndrome
|Shrinking lung syndrome
|
|
* A rare complication of SLE, that can cause dyspnea and shortness of with a reported prevalence of 0.5% of this overall population
* A rare complication of SLE, that can cause [[dyspnea]] and [[Dyspnea|shortness of breath]] (estimated prevalence approximately 0.5%).
|
|
|-
|-
Line 134: Line 135:
|[[Cardiomegaly]]  
|[[Cardiomegaly]]  
|
|
* Can be a result of:
* Due to:
** [[Myocarditis]]
** [[Myocarditis]]
** [[Libman-Sacks endocarditis]]
** [[Libman-Sacks endocarditis]]
Line 140: Line 141:
** [[Uremia]]
** [[Uremia]]
** [[Pulmonary arterial hypertension]] with right-sided heart failure
** [[Pulmonary arterial hypertension]] with right-sided heart failure
** Corticosteroid-related [[cardiomyopathy]]
** [[Corticosteroid]]-related [[cardiomyopathy]]
|
|
|-
|-
|[[Valvular disease]]
|[[Valvular disease]]
|
|
* Valvular involvement in systemic lupus erythematosus (SLE) is the most prevalent form of heart involvement in SLE
* Valvular involvement in systemic lupus erythematosus (SLE) is the most common form of cardiac involvement in SLE.
* Immunoglobulin and complement deposition in the valvular structure will lead to different valvular complications include Libman-Sacks vegetations, valve thickening, and valve regurgitation. Involvement of the mitral valve is most frequently encountered
* [[Immunoglobulin]] and [[complement]] deposition in the valvular structure will lead to different valvular complications include Libman-Sacks vegetations, valve thickening, and valve regurgitation.
* Mitral valve is the most frequently affected valve.
|
|
|-
|-
|[[Nonbacterial thrombotic endocarditis]]
|[[Nonbacterial thrombotic endocarditis]]
|
|
* An spectrum of noninfectious lesions of the heart valves that is most commonly seen in advanced malignancy
* An spectrum of noninfectious lesions of the heart valves that is commonly seen in advanced malignancy.
|
|
|-
|-
|[[Pericardial disease]]
|[[Pericardial disease]]
|
|
* The most important way that SLE can affect the heart is through pericardium and by causing an acute percarditis. It usually present as a positional sharp chest pain with radiation to the scapula
* The most important way that SLE can affect the heart is through pericardium and by causing an acute pericarditis. It usually present as a positional sharp chest pain with radiation to the scapula
|
|
|-
|-
Line 178: Line 180:
|[[Stroke]]
|[[Stroke]]
|
|
* Small vessel vasculopathy in thebrain during SLE disease is considered as one f the important factors in causing thrombosis and stroke in SLE patients
* Small vessel vasculopathy in the brain during SLE disease is considered as one f the important factors in causing thrombosis and stroke in SLE patients
|
|
|-
|-
Line 198: Line 200:
|
|
|-
|-
| rowspan="4" |Musculo-skeletal involvement
| rowspan="4" |Musculoskeletal involvement
|[[Arthritis]]
|[[Arthritis]]
|
|
Line 221: Line 223:
|
|
|-
|-
|Osteoprosis
|Osteoporosis
|
|
*Mostly due to [[glucocorticoid]] usage
*Mostly due to [[glucocorticoid]] usage
Line 241: Line 243:
|-
|-
|
|
|Nonscarring alopecia
|Non-scarring alopecia
|may occur at some point during the course of their disease
|may occur at some point during the course of their disease
|
|
Line 271: Line 273:
|}
|}
==Prognosis==
==Prognosis==
The prognosis of systemic lupus erythematosis is ranging from a benign illness to an extremely rapid progressive disease that can lead to a fulminant organ failure and death. Without treatment, systemic lupus eryhtematosus will result in a very high mortality rate, with a report of more than 60% mortality rate during the mid-20th century. SLE is associated with a 10 year mortality of more than 50% among patient with nephritis. The presence of nephritis is associated with a particularly poor prognosis among patients with SLE. The increase in survival rate of patients and better prognosis may be due to increased disease recognition with more sensitive diagnostic tests, earlier diagnosis or treatment, the inclusion of milder cases, increasingly judicious therapy, and prompt treatment of complications. Although improvement in SLE diagnosis have led to better prognosis, the mortality rate among SLE patients is still 5 times more than normal population.
The prognosis of systemic lupus erythematosus is ranging from a benign illness to an extremely rapid progressive disease that can lead to a fulminant organ failure and death. Without treatment, systemic lupus eryhtematosus will result in a very high mortality rate, with a report of more than 60% mortality rate during the mid-20th century. SLE is associated with a 10 year mortality of more than 50% among patient with nephritis. The presence of nephritis is associated with a particularly poor prognosis among patients with SLE. The increase in survival rate of patients and better prognosis may be due to increased disease recognition with more sensitive diagnostic tests, earlier diagnosis or treatment, the inclusion of milder cases, increasingly judicious therapy, and prompt treatment of complications. Although improvement in SLE diagnosis have led to better prognosis, the mortality rate among SLE patients is still 5 times more than normal population.


===== Poor prognostic factors for SLE survival: =====
===== Poor prognostic factors for SLE survival: =====

Revision as of 19:46, 11 July 2017

Systemic lupus erythematosus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Systemic lupus erythematosus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Lupus and Quality of Life

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Systemic lupus erythematosus natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Systemic lupus erythematosus natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Systemic lupus erythematosus natural history, complications and prognosis

on Systemic lupus erythematosus natural history, complications and prognosis

Systemic lupus erythematosus natural history, complications and prognosis in the news

Blogs onSystemic lupus erythematosus natural history, complications and prognosis

Directions to Hospitals Treating Systemic lupus erythematosus

Risk calculators and risk factors for Systemic lupus erythematosus natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Overview

Common complications of systemic lupus erythematosus include dermatitis, nephritis and arthiritis. Prognosis is generally poor, and the 10-year mortality rate of patients with systemic lupus erythematosus is approximately 40%. The disease course can be divided into 4 subcategories based on the course of the disease: developmental phase, preclinical phase, clinical phase, and comorbid complication phase.

Natural History

  • Systemic lupus erythematosus (SLE) is an autoimmune disease. SLE is a disease of waxing and waning, with possible flare up episodes. SLE usually develops in the second and third decade of life, although it can presents any age, and start with mild symptoms such as fatigue, fever, and skin rashes. Without treatment, the patient will develop symptoms of end organ damage, which will eventually lead to death in most of the patients.
  • The disease course can be divided into 4 subcategories based on the course of the disease:
Developmental phase:
Preclinical phase:
  • Mostly associated with auto-immune antibody production
  • Autoantibodies common to other systemic autoimmune diseases
  • Proceeds with a more disease-specific clinically overt autoimmune phase
Clinical phase:
  • The phase due to damages of the auto-antibodies to the body tissues (mostly related to disease itself)
  • Inflammation
  • Involvement of first organs
  • Flares
  • Involvement of additional organs
  • Early damages (e.g. alopecia, fixed erythema, cognitive dysfunction, valvular heart disease, avascular necrosis, tendon rupture, Jaccoud’s arthropathy, and osteoporosis)
Comorbidity-complication phase

Factors associated with flare up:

Complications

Complications that can develop as a result of prolonged activation of systemic lupus erythematosus or the SLE therapy are:

Organ Disease Description Frequency
Gastrointestinal system Dysphagia
  • The most frequent gastrointestinal complaint and is usually due to an underlying esophageal motility disorder, concomitant gastroesophageal reflux disease.
Peptic ulcer disease
  • May be due to the disease itself or the effect of SLE treatment.
Intestinal pseudo-obstruction
  • A rare complication of SLE and lead to mechanical obstruction of the small or large bowel in the absence of an anatomic lesion obstructing the flow of intestinal contents.
Protein-losing enteropathy
  • It typically occurs in patients with clinically severe SLE with multi-organ involvement and characterized with the onset of profound edema and hypoalbuminemia in the absence of nephrotic range proteinuria.
Hepatitis
  • May be due to a wide range of factors including drug-induced damage, steatosis, viral hepatitis, vascular thrombosis, overlap with autoimmune hepatitis, or SLE itself.
Acute pancreatitis
  • It occurs usually in the setting of active SLE.
Mesenteric vasculitis
Acute cholecystitis
Pulmonary involvement Pleural disease
Acute pneumonitis
  • A rare and fulminant form of diffuse lung injury that generally occurs in previously healthy individuals and has a rapid onset with fever, cough, and shortness of breath.
Pulmonary hemorrhage
  • Pulmonary alveolar hemorrhage:
    • A rare complication
    • Acutely ill patients with hemoptysis, fever, cough, and hypoxemia.
    • Blood loss can be extensive.
    • Associated with high mortality rates of 70%–90%
Pulmonary hypertension
Thromboembolic disease
  • Chronic inflammation during the disease flare ups is an important characteristic in SLE patients that increase the risk of thromboembolic events.
Shrinking lung syndrome
Cardiac involvement Cardiomegaly
Valvular disease
  • Valvular involvement in systemic lupus erythematosus (SLE) is the most common form of cardiac involvement in SLE.
  • Immunoglobulin and complement deposition in the valvular structure will lead to different valvular complications include Libman-Sacks vegetations, valve thickening, and valve regurgitation.
  • Mitral valve is the most frequently affected valve.
Nonbacterial thrombotic endocarditis
  • An spectrum of noninfectious lesions of the heart valves that is commonly seen in advanced malignancy.
Pericardial disease
  • The most important way that SLE can affect the heart is through pericardium and by causing an acute pericarditis. It usually present as a positional sharp chest pain with radiation to the scapula
Myocarditis
Coronary artery disease
  • Myocardial infarction (MI)
  • Narrowing of the small blood vessels that supply blood and oxygen to the heart as a result of accumulation of atheromatous plaques following autoimmune state of SLE
 ↑↑
Neurological involvement Cognitive dysfunction
  • The mental status of SLE patients can be temporarily affected by multiple, transient metabolic and systemic processes
Stroke
  • Small vessel vasculopathy in the brain during SLE disease is considered as one f the important factors in causing thrombosis and stroke in SLE patients
Seizures
  • Increased intracranial pressure can arise from a hypercoagulability state or thrombosis within the cerebral venous and can be the reason of seizures in these patients
Psychosis
  • Psychosis is fairly common in SLE and can indirectly influence cognitive performance as well. The psychosis in SLE patients is mostly accompanied by hallucinations
Neuropathies
  • Peripheral neuropathy prevalence is high in SLE and it is mostly related to disease activity
  • There is a greater chance for the patients with central nervous system involvement to show manifestation of peripheral neuropathy
  • There is a predilection for asymmetric and lower extremities involvement, especially peroneal and sural nerves
Musculoskeletal involvement Arthritis
  • Mostly symmetrical and non-erosive
  • Arthralgias
  • Effusions
  • Decreased range of motion of both small and large joints
  • Morning stiffness
Osteonecrosis (Avascular necrosis)
  • Most common in the femoral head
  • Can involve humeral head, tibial plateau, and scaphoid navicular 
  • Usually bilateral and is often asymptomatic
  • Glucocorticoids treatment is associated with the greatest risk of developing the disease
Subcutaneous nodules
  • In association with active disease
Osteoporosis
Skin disorder Cutaneous lupus erythematosus
  • Erythema in a malar distribution over the cheeks and nose (but sparing the nasolabial folds), which appears after sun exposure
Photosensitivity common theme for skin lesions associated with SLE
Non-scarring alopecia may occur at some point during the course of their disease
oral and/or nasal ulcers usually painless
discoid lesions more inflammatory and which have a tendency to scar
Very rare disorders Malignancy
Diabetes mellitus 
Premature gonadal failure

Prognosis

The prognosis of systemic lupus erythematosus is ranging from a benign illness to an extremely rapid progressive disease that can lead to a fulminant organ failure and death. Without treatment, systemic lupus eryhtematosus will result in a very high mortality rate, with a report of more than 60% mortality rate during the mid-20th century. SLE is associated with a 10 year mortality of more than 50% among patient with nephritis. The presence of nephritis is associated with a particularly poor prognosis among patients with SLE. The increase in survival rate of patients and better prognosis may be due to increased disease recognition with more sensitive diagnostic tests, earlier diagnosis or treatment, the inclusion of milder cases, increasingly judicious therapy, and prompt treatment of complications. Although improvement in SLE diagnosis have led to better prognosis, the mortality rate among SLE patients is still 5 times more than normal population.

Poor prognostic factors for SLE survival:
  • Presence of nephritis (especially diffuse proliferative glomerulonephritis)
  • Hypertension
  • Male sex
  • Young age
  • Older age at presentation
  • Low socioeconomic status
  • Black race: Higher rate of nephritis
  • Presence of antiphospholipid antibodies
  • High overall disease activity
Prognosis markers:
  • Serum anti-dsDNA titres correlated with:
    • Lupus nephritis
    • Progression to end-stage renal disease
    • Increased disease severity
    • Damage or poor survival
  • Antiphospholipid antibodiescorrelated with
    • Features of the antiphospholipid syndrome (APS) (arterial/ venous thrombosis, fetal loss, thrombocytopenia)
    • CNS involvement (especially cerebrovascular disease)
    • Severe lupus nephritis
    • Damage accrual
    • Increase in mortality rate
SLE in men compared to women:
  • Less photosensitivity
  • More serositis
  • Older age at diagnosis
  • Higher 1 year mortality compared to women.
SLE in the elderly (>65) compared to middle age prevalency:
  • Lower incidence of:
    • Malar rash
    • Photosensitivity
    • Purpura
    • Alopecia
    • Raynaud’s phenomenon
    • Renal system involvement
    • Central nervous system involvement
  • Greater prevalence of:
    • Serositis
    • Pulmonary involvement
    • Sicca symptoms
    • Musculoskeletal manifestations

References

2

Retrieved from "https://www.wikidoc.org/index.php?title=Systemic_lupus_erythematosus_natural_history,_complications_and_prognosis&oldid=1325193"